沈陽藥科大學(xué)獲得學(xué)士、中科院碩士、長(zhǎng)江商學(xué)院EMBA 碩士?，F(xiàn)任啟明創(chuàng)投醫(yī)療健康投資合伙人。 唐女士加入啟明前，在晨興創(chuàng)投工作13年，擔(dān)任晨興北京辦公室總經(jīng)理。在此期間，獨(dú)立投資并在董事會(huì)層面管理超過20家早期生物醫(yī)藥公司。 其中大部分均已通過上市或并購(gòu)?fù)緩匠晒ν顺?，回?bào)豐厚。加入晨興之前，唐女士在葛蘭素史克工作七年，其中五年做新藥注冊(cè)，兩年做產(chǎn)品經(jīng)理。 在啟明工作期間，投資項(xiàng)目包括神州細(xì)胞，義翹神州，加科思，科州，克?；?，和其瑞等公司。 ? Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB). Ms. Amy Tang is a Venture Partner at Qiming Venture Partners. Amy previously worked in Morningside Ventures for 13 years in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns. Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years. ? |